1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Diamondback Energy and its subsidiary Diamondback E&P LLC signed a seventeenth amendment to their credit agreement with Wells Fargo as administrative agent on June 12, 2026. The amendment extends the maturity by one year, raises total lender commitments by $500 million, and lowers the interest rate on loans and certain fees. The filing does not state how much of the facility is drawn, so the financial effect on the company is not quantified.
Maturity extended from June 12, 2030 to June 12, 2031
Total commitments increased from $2.5 billion to $3.0 billion
Interest rate on loans and certain fees decreased; the filing does not give the new rate
Full amendment filed as Exhibit 10.1; signed June 15, 2026 by Teresa L. Dick, Executive Vice President and Chief Accounting Officer
Viper Energy and its subsidiary VNOM Sub, Inc. signed a first amendment to the credit agreement on June 12, 2026, with Wells Fargo Bank as administrative agent. The amendment raises total lender commitments from $1.5 billion to $2.0 billion, extends the maturity date from June 12, 2030 to June 12, 2031, and lowers the interest rate and certain fees on loans.
Total commitments under the Credit Agreement increased from $1.5 billion to $2.0 billion.
Maturity date extended from June 12, 2030 to June 12, 2031.
Interest rate on loans and certain fees payable under the agreement decreased.
Borrower is Viper Energy Partners LP; Wells Fargo Bank, National Association is administrative agent.
RF Industries reported fiscal second-quarter 2026 results for the quarter ended April 30, 2026. Net sales rose 9% year over year to $20.7 million, and consolidated net income was $879,000, or $0.08 per diluted share, compared with a net loss of $245,000 a year earlier, which helps show improved profitability for shareholders.
Net sales were $20.7 million, up 9% from $18.9 million a year earlier and up from $19.0 million in the first quarter of fiscal 2026.
Gross profit margin was 35.1%, up from 31.5% in the prior-year period; operating income was $1.1 million versus $106,000.
Consolidated net income was $879,000 ($0.08 per diluted share) versus a loss of $245,000 ($0.02 per share) a year earlier.
Backlog was $20 million at quarter-end on second-quarter bookings of $26.3 million; adjusted EBITDA was $2 million versus $1.1 million.
Rhythm Pharmaceuticals released interim six-month data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome, with 17 patients on active therapy and a data cut-off of May 7, 2026. The company reported mean BMI reductions, fat loss with preserved lean mass, and hyperphagia improvements, and said the results reinforce its rationale for Phase 3 development in PWS. The trial is small, open-label and ongoing for 52 weeks, so the results do not yet establish efficacy.
Mean BMI reduction at Month 6 was -3.06% (n=17), with -3.11% in adults (n=10) and -3.00% in pediatric patients (n=7)
Mean fat mass change was -4.19% and mean lean mass change was +0.74% across 16 patients with DEXA data
Eight of 10 patients with moderate to severe hyperphagia achieved a 7-point or greater HQ-CT improvement
The 52-week trial remains ongoing, with 17 patients on active therapy as of June 12, 2026
Credit Acceptance amended its revolving secured line of credit with Fifth Third Bank as administrative agent, extending the date the facility stops revolving from June 22, 2028 to June 22, 2029. The interest rate spread was lowered from SOFR plus 197.5 basis points to SOFR plus 175.0 basis points, and the company had $270.5 million outstanding under the facility as of June 9, 2026. The filing states there were no other material changes to the facility's terms.
Amendment dated June 9, 2026 extends the facility's revolving period end date to June 22, 2029
Interest rate spread reduced from SOFR plus 197.5 basis points to SOFR plus 175.0 basis points
$270.5 million outstanding under the facility as of June 9, 2026
American Express disclosed monthly credit statistics for its U.S. Consumer and U.S. Small Business card balances held for investment through May 31, 2026. Delinquency rates fell in both portfolios, and total balances rose to $160.5 billion from $157.2 billion in April. Net write-off rates were mixed, with the Consumer rate easing and the Small Business rate rising.
U.S. Consumer 30-plus days past due fell to 1.1% in May, from 1.2% in April and 1.3% in March.
U.S. Small Business 30-plus days past due fell to 1.4% in May, from 1.5% in April and 1.6% in March.
U.S. Consumer net write-off rate was 2.0% in May, down from 2.1% in April; Small Business rose to 2.6% from 2.4%.
Total card balances held for investment were $160.5 billion at May 31, 2026, up from $157.2 billion at April 30.
Context Therapeutics filed a press release and conference call materials on interim Phase 1a data for CTIM-76, its Claudin 6 x CD3 bispecific antibody, which the company describes as showing efficacy and safety signals in heavily pretreated patients. The sample is small (13 patients in all comers and 10 RECIST-evaluable at target doses, as of May 29, 2026), and the company states that clinical data are preliminary. The company also expects cash runway into mid-2027 and anticipates further CTIM-76 data in Q4 2026.
As of May 29, 2026, 2 of 10 RECIST-evaluable patients at target doses (140 to 280 µg) had confirmed overall response, and 5 of 10 had disease control.
Grade 1 cytokine release syndrome (CRS) was reported in 16% of all-comers patients (n=13) at target doses, with no Grade 2 or higher CRS in that group.
Updated CTIM-76 data are anticipated in Q4 2026, and preliminary Phase 1a data for the CT-95 mesothelin program are expected in September 2026.
Roku entered a merger agreement under which Fox Corporation will acquire Roku in a cash-and-stock deal valued at $160.00 per Roku share, or about $22 billion in enterprise value. Roku stockholders would receive $96.00 in cash and 0.9693 Fox Class A shares per share, and Roku's Class A stock would be delisted from Nasdaq if the deal closes, which is expected in the first half of calendar 2027.
Consideration: $96.00 in cash plus 0.9693 Fox Class A shares per Roku share, with the stock portion based on a $66.03 reference price as of June 10, 2026
Roku stockholders are expected to own about 27% of the combined company
Closing is subject to Roku and Fox shareholder approvals and U.S. and certain non-U.S. regulatory approvals; a Roku holder group controlling at least a majority of voting power has agreed to vote in favor
Fox has obtained $12.0 billion of committed bridge financing from Morgan Stanley Senior Funding
On June 12, 2026, Peabody's Australian subsidiaries entered two surety bond facilities with combined commitments of A$700 million, replacing cash-collateralized reclamation bonding programs. The same day, the company terminated its 2020 Transaction Support Agreement with its surety providers after satisfying all obligations under it. The company says the changes are expected to reduce total reclamation collateral requirements and eliminate a minimum liquidity covenant.
June 12, 2026: Australian subsidiaries entered surety bond facilities with Liberty and Swiss Re International SE, with combined commitments of A$700 million maturing June 12, 2031.
The new facilities replace the Australian subsidiaries' existing 100% cash-collateralized programs and are secured by substantially all of the obligors' assets.
June 12, 2026: Peabody terminated the 2020 Transaction Support Agreement with its sureties; all obligations under it were satisfied.
Peabody says the combined transactions are expected to reduce total reclamation collateral requirements and eliminate a minimum liquidity covenant.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.